New antibody drug JMT108 enters human trials for tough cancers

NCT ID NCT07317505

Recruiting now Disease control Sponsor: Conjupro Biotherapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests JMT108, a bispecific antibody, in 270 adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. Participants receive JMT108 by IV every two weeks and are monitored closely.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer colorectal neoplasm gastric neoplasm Liver Neoplasms melanoma neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CANCER CANCER (SOLID TUMORS)

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Carolina BioOncology Institute
RECRUITING

Huntersville, North Carolina, 28078, United States

Contact
NEXT Dallas
RECRUITING

Dallas, Texas, 75039, United States

Contact
NEXT Virginia
RECRUITING

Fairfax, Virginia, 22031, United States

Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.